Final report

  • 08:58

Immunicum submits the final report for its phase I/II trial in metastatic renal cell carcinoma showing positive safety data and promising survival data.

Immunicum® AB (publ) today submitted the final report to the Swedish Medical Products Agency regarding its clinical phase I/II study in 12 patients with newly diagnosed kidney cancer, treated with the cancer vaccine INTUVAX®. No vaccine-related serious adverse events were noted and the report presents a hitherto achieved median survival for patients with poor prognosis that clearly exceeds the expected median survival for patients treated with established drugs that are often associated with serious side effects. Data also shows clear signs of tumor-specific immune activation.


Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4913

Comments are closed.